Inmune Bio (INMB) Total Non-Current Liabilities (2021 - 2023)

Inmune Bio (INMB) posted Total Non-Current Liabilities of $17.2 million for Q3 2023, down 18.82% sequentially from $21.1 million in Q4 2022.

Inmune Bio (INMB) Total Non-Current Liabilities (2021 - 2023) Analysis & Trends

Inmune Bio has reported Total Non-Current Liabilities for 3 years, with the latest figure at $17.2 million in Q3 2023.

Quarterly Total Non-Current Liabilities changed N/A year-over-year to $17.2 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $17.2 million (changed N/A YoY) and the FY2022 annual result came in at $21.1 million, up 7.21% from the prior year.
Total Non-Current Liabilities eased to $17.2 million in Q3 2023 per INMB's latest filing, from $21.1 million in the prior quarter.
Over five years, Total Non-Current Liabilities peaked at $21.1 million in Q4 2022 and troughed at $17.2 million in Q3 2023.
A 3-year average of $18.9 million and a median of $18.9 million in 2021 frame the typical range for Total Non-Current Liabilities.
The widest YoY moves for Total Non-Current Liabilities: up 7.21% in 2022, down 7.21% in 2022.
Over 3 years, Total Non-Current Liabilities stood at $19.7 million in 2021, then rose by 7.21% to $21.1 million in 2022, then slipped by 18.82% to $17.2 million in 2023.
According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $17.2 million, $21.1 million, and $18.7 million for Q3 2023, Q4 2022, and Q1 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Non-Current Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.92 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	7.74 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	40.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	3.92 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.88 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	4.20 Bn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	724.15 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.17 Bn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	9.32 Bn
10	Inmune Bio	61.59 Mn	43.18 Mn	-	-

Download Data